Recent Updates
Recently added Catalysts

Abeona Therapeutics Inc.

ABEO
Richly ValuedPharma · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$4.96
▼ -0.08 · -1.57%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ABEO financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $4.0052W HIGH $7.65
Volume
1.63 M
Value Traded
8.64 M
Short % Float
31.06%
-1.39%Week
-14.34%1 Month
-28.94%3 Month
+1.02%6 Month
-86.4%5 Year
-100%All Time

Cash Data

Unlock ABEO cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
283.63 M
EPS (TTM)
-1.10
P/E Ratio
-
Ent. Value
165.13 M
Total Shares
57.18 M
Float Shares
50.70 M
Insiders
11.33%
Institutions
69.07%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every ABEO catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ABEO Catalyst Timeline

Dated clinical, regulatory and corporate events for Abeona Therapeutics Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Abeona Therapeutics Inc.

900Total events
4Upcoming
129Tier-1 (high impact)
2014 to 2026Coverage

Upcoming catalysts 2

T2IND Submission
Subscribe to view catalyst details
ABO-701
T2Timing Guidance
Subscribe to view catalyst details

Event history 50

▲Enrollment MilestoneZEVASKYNApprovedTrial
Cincinnati Children's activated as newest ZEVASKYN QTC in Q3 2026
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
▲Manufacturing MilestoneZEVASKYNApprovedCMC / Inspection
Cincinnati Children's activated as newest ZEVASKYN QTC in Q3 2026
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
●Equity OfferingCorporate
Restricted stock equity awards granted to two new non-executive employees
source ↗
●Grant / FundingCorporate
Restricted stock inducement grants to two new employees
source ↗
▲FDA ApprovalFAYUVIApprovedFDA Decision
FDA approves FAYUVI (rebisufligene etisparvovec-hopf) for MPS IIIA
Sanfilippo syndrome type A (mucopolysaccharidosis IIIA, or MPS IIIA)source ↗
▲Manufacturing MilestoneZEVASKYNApprovedCMC / Inspection
University of Florida Health activated as eighth Qualified Treatment Center for ZEVASKYN
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
▲Product LaunchZEVASKYNApprovedPost-Market
University of Florida Health activated as eighth Qualified Treatment Center for ZEVASKYN
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
▲Timing GuidanceZEVASKYNApprovedPresentation
University of Florida Health activated as eighth Qualified Treatment Center for ZEVASKYN
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
▲Enrollment UpdateZEVASKYNApprovedTrial
UF Health initiated patient identification and onboarding activities for ZEVASKYN treatment
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
●Quarterly UpdateCorporate
Conference call and webcast on August 13, 2026
source ↗
Unlock the full ABEO catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ABEO actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-04-29Prademagene zamikeracel (pz-cel) PDUFA Date ApprovedPDUFA
Unlock 3 more ABEO historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D31 / 100
Pipeline Score
$0M
Pipeline Value
$26M
Commercial Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 65%
Micro Cap
(rank 428 of 658)
Percentile Rank
Abeona Therapeutics Inc. faces pipeline headwinds (31/100), with 1 assets in development.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $25.5M x 1.0 = $26M
ProductRevenuePrior periodChange
ZEVASKYN$23M--
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets Monoclonal antibodyCompletedNCT01263379Epidermolysis Bullosa DystrophicaPhase 1 COMPLETED 12Mar 9, 2022
Unlock the ABEO pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ABEO program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
ZEVASKYN
PriorityOrphanRare Pediatric
recessive dystrophic epidermolysis bullosaPhase 32025-06-24significant improvements in wound healing and pain reduction following a single treatmentRead MoreAbeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis BullosaRead More
Scroll for more · summaries link to the source press release
Unlock every ABEO trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ABEO insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Vasanthavada MadhavOfficer (Chief Commercial Officer)Sell -4,902 285,721 held$5.16 09/29/2026
Unlock the full ABEO insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in ABEO

Fund % of Portfolio Current MV Shares Owned Activity
SILVERARC CAPITAL MANAGEMENT, LLC 0.4 % (33.3 %) 3.77 M 610.41 K -5.94% ( -38.53 K)
Unlock every fund holding ABEO
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ABEO
Shares held by hedge funds each quarter, and who bought or sold.

ABEO Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-10-16
Unlock ABEO option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ABEO option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ABEO options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ABEO ranks across every disease it competes in

Competitive Position is a premium feature
See how ABEO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ABEO News

ABEO
Oct 2, 2026
ABEOGeneral

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics announced the granting of equity awards to new non-executive employees as an inducement to employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The awards, totaling up to 7,200 restricted shares, will vest over three years. This move reflects the company's commitment to attract and retain talent while advancing its gene therapy initiatives.

Read more →
ABEO
Sep 18, 2026
ABEOFDA Updates

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics congratulated Ultragenyx on the FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A. This approval marks a significant achievement for patients suffering from this rare disease, which has limited treatment options. The therapy was developed from research at The Ohio State University and was advanced by Abeona before being licensed to Ultragenyx. Abeona is set to receive milestone payments and royalties from future sales.

Read more →
ABEO
Sep 16, 2026
ABEOGeneral

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics has activated the University of Florida Health as the eighth Qualified Treatment Center for ZEVASKYN, a gene-modified therapy for recessive dystrophic epidermolysis bullosa (RDEB). This partnership aims to enhance access to innovative treatment for patients in Florida and the Southeastern U.S. ZEVASKYN is designed to improve wound healing in RDEB patients by incorporating the COL7A1 gene into their skin cells.

Read more →
ABEO
Sep 2, 2026
ABEOConferences/Events

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics Inc. announced its participation in several investor conferences in September 2026. The events include the Cantor Global Healthcare Conference, H.C. Wainwright 28th Annual Global Investment Conference, and Morgan Stanley 24th Annual Global Healthcare Conference. Management will engage in fireside chats and investor meetings, enhancing the company's visibility in the investment community.

Read more →
ABEO
Aug 13, 2026
ABEOGeneral
▼ -14.9%on this news

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

Abeona Therapeutics reported a 31% increase in ZEVASKYN revenue for Q2 2026, totaling $11.4 million. The company treated five patients with ZEVASKYN in Q2 and expanded its qualified treatment center network to seven sites. Notably, ZEVASKYN received CMS New Technology Add-On Payment status, expected to improve access for Medicare patients. However, the company reported a net loss of $(20.2) million for the quarter.

Read more →
ABEO
Aug 6, 2026
ABEOConferences/Events

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

Abeona Therapeutics Inc. will hold a conference call on August 13, 2026, to discuss its second quarter financial results and provide a corporate update. The call will be accessible via phone and a live webcast. The company is known for its development of cell and gene therapies, including ZEVASKYN for treating RDEB.

Read more →
ABEO
Aug 4, 2026
ABEOFDA Updates
▲ +6.7%on this newsshared move

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

Abeona Therapeutics announced that CMS has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN, enhancing reimbursement for this innovative therapy. This designation aims to support patient access and treatment center economics. ZEVASKYN is the first autologous cell sheet-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

Read more →
ABEO
Jul 21, 2026
ABEOGeneral

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics has announced the activation of Cincinnati Children's as the seventh Qualified Treatment Center for ZEVASKYN, a novel gene-modified therapy for recessive dystrophic epidermolysis bullosa (RDEB). This collaboration aims to improve access to ZEVASKYN for patients suffering from this severe skin condition. The therapy has shown promising results in wound healing and pain reduction.

Read more →
ABEO
Jun 1, 2026
ABEOGeneral

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics announced the granting of equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4). On May 31, 2026, the company's Compensation Committee approved 13,800 restricted shares as an inducement for the seven newly hired individuals. The vesting period for these awards spans three years, contingent upon continued employment. This move underscores Abeona's strategy to attract and retain talented personnel as it continues to develop its pipeline of cell and gene therapies.

Read more →
ABEO
May 26, 2026
ABEOConferences/Events

Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics Inc. will participate in significant investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. The management team will engage with investors, highlighting their focus on advancing cell and gene therapies for serious diseases. The events will also feature a live webcast of a fireside chat, accessible on their website. This engagement reflects Abeona's commitment to their innovative therapies and maintaining investor relations.

Read more →
ABEO
May 13, 2026
ABEOGeneral

Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

Abeona Therapeutics reported strong first quarter results for 2026, highlighting increased adoption of ZEVASKYN with three patients treated. The company expanded its qualified treatment center network to six sites, enhancing patient access. Financially, Abeona saw a significant rise in net product revenue, although it also reported a net loss of $(17.1) million for the quarter.

Read more →
ABEO
May 11, 2026
ABEOGeneral

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics has announced the activation of the Children's Hospital of Philadelphia as a Qualified Treatment Center for ZEVASKYN, a gene-modified therapy for recessive dystrophic epidermolysis bullosa (RDEB). This collaboration aims to improve access to treatment for patients in the east coast. ZEVASKYN has demonstrated significant wound healing and pain reduction, although there are potential risks associated with its use.

Read more →
ABEO
May 4, 2026
ABEOConferences/Events
▲ +9.6%on this news

Abeona Therapeutics® Announces Date of First Quarter Financial Results

Abeona Therapeutics Inc. announced a conference call scheduled for May 13, 2026, to discuss its first quarter financial results and corporate progress. The call will be accessible via phone and webcast. The company is known for its ZEVASKYN gene therapy, which targets recessive dystrophic epidermolysis bullosa, and is actively developing additional therapies.

Read more →
ABEO
Apr 7, 2026
ABEOGeneral

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Abeona Therapeutics has appointed Keith A. Goldan to its Board of Directors as of April 1, 2026. Goldan, who has over two decades of financial leadership experience, will also chair the Audit Committee. His expertise is anticipated to support Abeona's growth as a commercial-stage biotech company, particularly in advancing its strategic priorities.

Read more →
ABEO
Apr 2, 2026
ABEOGeneral
▲ +5.2%on this newsshared move

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

Abeona Therapeutics has activated NewYork-Presbyterian/Columbia University Irving Medical Center as a Qualified Treatment Center for ZEVASKYN, enhancing patient access in the Northeast. This partnership aims to provide world-class care for patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is the first gene-modified cellular therapy for this condition, demonstrating significant healing potential.

Read more →

About Abeona Therapeutics Inc.

Cleveland, OH 226 employees abeonatherapeutics.com
Headquarters6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, OH, 44103
Founded1974
BIOPHARMAWATCH ELITE PLUS
Trade the next ABEO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime